| abstract |
The invention discloses the application of CORMs in the preparation of anti-idiopathic pulmonary fibrosis drugs, and belongs to the technical field of medicine. The medicament includes an effective amount of CORMs and a pharmaceutically acceptable carrier, the CORMs include CORM2 and CORM3, and the CORMs can reduce bleomycin-induced collagen deposition and down-regulate α- in idiopathic pulmonary fibrosis subjects The mRNA expression levels of SMA, TGF-β, p53, PAI-1 and IL-1β and the reduction of ROS generation in subjects with idiopathic pulmonary fibrosis, which will provide new treatments for the clinical treatment of idiopathic pulmonary fibrosis It also lays a theoretical and experimental foundation for the development of innovative drugs with independent intellectual property rights. |